Senti Biosciences
Outsmarting complex diseases with more intelligent medicines
South San Francisco, United States
66 employees
Grant
Total: $223.90M
Biotechnology, Health Care +1
General Information
South San Francisco, United States
BounceWatch is an independent company data service, not affiliated with Senti Biosciences. To contact Senti Biosciences, visit sentibio.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Senti Biosciences compare?
A PDF of Senti Biosciences and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Senti Biosciences soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
From the desk
Is Senti Biosciences on your competitive set?
Our desk can watch it and brief you on every move: hiring, funding, leadership, product and pricing.
Book a 7-day ReadoutDiscover More
United States Market
Biotechnology
About Senti Biosciences
Business keywords: synthetic biology, cell therapy, gene therapy, biological logic, disease treatment, smart medicine, gene circuits, DNA sequences, complex diseases, therapeutic effectiveness, medical innovation
Funding Rounds & Investors (11)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Grant | $8.00M | 1 |
California Institute for Regenerative Medicine
|
01 Jul 2024 |
| Post IPO Equity | $50.60M | 9 |
|
09 Jun 2022 |
| Convertible Note | $5.18M | 1 |
|
24 May 2022 |
| Grant | $1.90M | 1 |
National Cancer Institute
|
28 Sep 2021 |
| Series B | Undisclosed | 2 |
|
14 May 2021 |
| Series B | $105.00M | 10 |
|
06 Jan 2021 |
| Series A | Undisclosed | 2 |
|
20 Aug 2020 |
| Series A | Undisclosed | 1 |
|
16 Jan 2019 |
| Series A | $53.00M | 10 |
|
27 Feb 2018 |
| Grant | $225.00K | 1 |
|
19 Dec 2017 |
Senti Biosciences Alternatives & Competitors
View All Alternatives
Where synthetic biology meets RNA therapeutics
Pioneering epigenetic medicine for complex diseases
Precigen (Nasdaq: PGEN) is a biopharmaceutical company advancing the next generation of gene and cel...
FAQ About Senti Biosciences
Source: BounceWatch company record for Senti Biosciences, https://bouncewatch.com/company/senti-biosciences, updated 9 June 2026. When citing, please name BounceWatch and link this page.
